Older Adults Living in Sheltered Housing’s Experiences of Involvement in Pro Re Nata Decisions. A Narrative Positioning Analysis [PDF]
Global Qualitative Nursing Research, 2021 Decisions regarding pro re nata medications might be challenging due to the complex nature of the practice. The aim of this study was to expand our understanding of the experiences of older people living in sheltered housings with regard to shared ...
Marianne Kollerøs Nilsen +3 more
doaj +5 more sources
Patient Safety and Pro Re Nata Prescription and Administration: A Systematic Review [PDF]
Pharmacy, 2018 PRN is the acronym for ‘pro re nata,’ written against prescriptions whose administration should be based on patients’ needs, rather than at set times.
Mojtaba Vaismoradi +2 more
doaj +8 more sources
A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration [PDF]
Frontiers in Medicine, 2022 PurposeTo compare the efficacy and safety of conbercept using a treat-and-extend (T&E) regimen vs. a pro re nata (PRN) regimen in Chinese patients with neovascular age-related macular degeneration (nAMD).MethodsThis was a randomized, multicenter, non-
Huixun Jia +22 more
doaj +2 more sources
The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the “Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)” project [PDF]
Annals of General Psychiatry, 2022 Background Several guidelines recommend monotherapy in pharmacotherapy for schizophrenia and major depressive disorder. The content of regular prescriptions has been reported in several studies, but not enough research has been conducted on the content ...
Yoshitaka Kyou +38 more
doaj +2 more sources
Treat-and-Extend vs. Pro Re Nata Regimen of Ranibizumab for Diabetic Macular Edema—A Two-Year Matched Comparative Study [PDF]
Frontiers in Medicine, 2022 PurposeTo compare 2-year treatment outcomes of ranibizumab using treat-and-extend (T&E) or pro re nata (PRN) regimens for diabetic macular edema (DME) in clinical settings.MethodsWe retrospectively enrolled 34 patients (34 eyes) with DME treated with
Tso-Ting Lai +8 more
doaj +2 more sources
Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study. [PDF]
J Clin Med, 2021 The present study aimed to determine the efficacy and safety of pro re nata (PRN) intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) without a loading dose in the real-world setting. The PROBE study (Pro Re Nata Brolucizumab for Exudative AMD) is a retrospective, observational, multicentric study that included 27 ...
Bilgic A +8 more
europepmc +4 more sources
Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis [PDF]
International Journal of Retina and Vitreous, 2022 Background Aflibercept is a relatively new anti-VEGF used to treat neovascular age-related macular degeneration (AMD). The purpose of this review is to evaluate the effect of pro re nata (PRN) and fixed regimen (bimonthly) of aflibercept injection for ...
Andi Arus Victor, Yan Martha Putri
doaj +2 more sources
Ten-year real-world outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration using pro re nata regimen [PDF]
BMJ Open Ophthalmology, 2023 Background/aims To analyse long-term outcomes of antivascular endothelial growth factor (anti-VEGF) therapy for the treatment of neovascular age-related macular degeneration (nAMD) using pro re nata (PRN) regimen in a single-centre clinical practice ...
Anja Tuulonen +8 more
doaj +2 more sources
Use of Psychotropic “Pro Re Nata” Medications by Patients Attending the Outpatient Clinic in a Hospital: A Qualitative Exploration [PDF]
Frontiers in Medicine, 2021 Introduction: Administration of psychotropic pro re nata (PRN) medications is influenced by diverse factors such as legal use of PRN medications, the attitude of patients, personal bias, and stigma toward such medication use.
Kingston Rajiah +3 more
doaj +2 more sources
Brolucizumab versus aflibercept in treating exudative age-related macular degeneration: a 12-month pro re nata regimen [PDF]
Scientific ReportsWe compared 12-month treatment outcomes of intravitreal injections of brolucizumab (IVBr) with aflibercept (IVA) for treatment-naïve exudative age-related macular degeneration (AMD).
Wataru Kikushima +6 more
doaj +2 more sources